Drug intelligence / Profile preview

obrindatamab

Development stage: Discontinued
Lead developer: MacroGenics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Obrindatamab is a humanized bispecific antibody (DART protein) developed by MacroGenics for the treatment of cancer. It simultaneously targets B7-H3 (CD276) on tumor cells and CD3 on T cells. By binding to both antigens, obrindatamab redirects cytotoxic T lymphocytes to attack and kill B7-H3-expressing cancer cells through antibody-dependent cell cytotoxicity and T-cell activation. The drug was primarily investigated in solid tumors but its development has been discontinued[1][2][3][5].

Other names: obrindatamabMGD-009MGD009MGD 009orlotamab

Targets

B7-H3CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on obrindatamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on obrindatamab.

Explore the full profile